Jazz Pharmaceuticals Story

Jazz Pharmaceuticals Public Limited Company -- USA Stock  

USD 157.95  2.31  1.48%

Macroaxis does not monitor all media channels or aggregates social signals for Jazz Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Jazz Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Jazz Pharmaceuticals. Please also check Jazz Pharmaceuticals Hype Analysis, Jazz Pharmaceuticals Correlation and Jazz Pharmaceuticals Performance.
Acquisition by Paul Berns of 4500 shares of Jazz Pharmaceuticals subject to Rule 16b-3
Filed transaction by Jazz Pharmaceuticals Plc director. Grant, award or other acquisition pursuant to Rule 16b-3

Jazz Pharmaceuticals Public Limited Company insider trading alert for grant of nonstatutory stock option (right to buy) by Paul Berns, the corporate stakeholder, on January 3, 2018. This event was filed by Jazz Pharmaceuticals Plc with SEC on 2013-08-12. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The trading delta at closing time against the next closing price was 1.58% . The trading delta at closing time when the story was published against the current closing price is 13.95% .

Similar stores for Jazz Pharmaceuticals

a day ago at http://bzweekly.com 
Kinder Morgan Del Shareholder Jrm Investment Counsel Trimmed Its Holding by 884556 as Shares Declined ...
news
BZ WeeklyFull coverage
over three weeks ago at http://bzweekly.com 
New York Jazz Pharmaceuticals Stock Has Just Had Its Buy Rating Reiterated by Cantor Fitzgerald ...
news
BZ WeeklyKey Equity Research Analysts at Cantor Fitzgerald Kept the Same their Buy rating for Jazz Pharmaceuticals Shareholder Ulysses Management Has Cut Its Position by 1.50 Million as Valuation Rose Rdl ... UtahHerald.comFull coverage
over two months ago at www.macroaxis.com 
Acquisition by Patrick Enright of 1858486 shares of Jazz Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Jazz Pharmaceuticals Plc director. Grant, award or other acquisition pursuant to Rule 16b-3

Did you try this?

Run Price Ceiling Movement Now
   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
View All  Next Launch Price Ceiling Movement

Current Liabilities

Current Liabilities Comparative Analysis
  Current Liabilities 
      Jazz Pharmaceuticals Comparables 
Jazz Pharmaceuticals is currently under evaluation in current liabilities category among related companies. Current Liabilities is company's short term debts. This usually includes obligations that are due within next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Peers

Jazz Pharmaceuticals Related Equities
MNK  5.28 %   
0%
100.0%
ABT  0.59 %   
0%
11.0%
BMY  0.53 %   
0%
10.0%
ENDP  0.18 %   
3.0%
0%
BIO  0.31 %   
5.0%
0%
VRTX  0.34 %   
6.0%
0%
AGN  0.86 %   
16.0%
0%
LLY  1.42 %   
26.0%
0%
MRK  2.36 %   
44.0%
0%
Please also check Jazz Pharmaceuticals Hype Analysis, Jazz Pharmaceuticals Correlation and Jazz Pharmaceuticals Performance. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.